Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Jami Kinnucan's publication output changed over time?
ScholarIQpublication output · 2013–2024
Output declined50% over the shown period — from 2 works in 2013 to 1 in 2024.
2
3
3
1
1
1
201320182019202020212024
What are the most-cited papers on Jami Kinnucan?
ScholarIQmost cited works
Inflammation Is an Independent Risk Factor for Colonic Neoplasia in Patients With Ulcerative Colitis: A Case–Control Study
David T. Rubin, Dezheng Huo, Jami Kinnucan, Mina S. Sedrak, Nicole E. McCullom, Alana Bunnag, Elin P. Raun–Royer, Russell D. Cohen, Stephen B. Hanauer, John Hart, Jerrold R. Turner
Clinical Gastroenterology and Hepatology. 2013296 CitationsOPEN ACCESS
Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study
Jeffrey Berinstein, Jessica L. Sheehan, Michael Dias, Elliot Berinstein, Calen A. Steiner, Laura A. Johnson, Randolph E. Regal, John I. Allen, Kelly C. Cushing, Ryan W. Stidham, Shrinivas Bishu, Jami Kinnucan, Shirley Cohen‐Mekelburg, Akbar K. Waljee, Peter Higgins
Clinical Gastroenterology and Hepatology. 2021138 CitationsOPEN ACCESS
Efficacy of Induction Therapy With High-Intensity Tofacitinib in 4 Patients With Acute Severe Ulcerative Colitis
Jeffrey Berinstein, Calen A. Steiner, Randolph E. Regal, John I. Allen, Jami Kinnucan, Ryan W. Stidham, Akbar K. Waljee, Shrinivas Bishu, Leslie B. Aldrich, Peter Higgins
Clinical Gastroenterology and Hepatology. 2018108 CitationsOPEN ACCESS
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease
Britt Christensen, Dejan Micić, Peter G. Gibson, Andrés Yarur, Emanuelle Bellaguarda, Paul M. Corsello, John N. Gaetano, Jami Kinnucan, Vijaya L. Rao, S. Reddy, Siddharth Singh, Joel Pekow, David T. Rubin
Alimentary Pharmacology & Therapeutics. 201887 CitationsOPEN ACCESS
CD4+ Tissue-resident Memory T Cells Expand and Are a Major Source of Mucosal Tumour Necrosis Factor α in Active Crohn’s Disease
Shrinivas Bishu, Mohamad El‐Zaatari, Atsushi Hayashi, Guoqing Hou, Nicole Bowers, Jami Kinnucan, Beth Manoogian, Michelle M. Muza–Moons, Min Zhang, Helmut Grasberger, Charlie Bourque, Weiping Zou, Peter Higgins, Jason R. Spence, Ryan W. Stidham, Nobuhiko Kamada, John Y. Kao
Journal of Crohn s and Colitis. 201974 CitationsOPEN ACCESS
Related on ScholarIQ
Jacksonville College
Institution
Inflammation Is an Independent Risk Factor for Colonic Neoplasia in Patients With Ulcerative Colitis: A Case–Control Study
Paper
Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study
Paper
Efficacy of Induction Therapy With High-Intensity Tofacitinib in 4 Patients With Acute Severe Ulcerative Colitis
Paper
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease
Paper
CD4+ Tissue-resident Memory T Cells Expand and Are a Major Source of Mucosal Tumour Necrosis Factor α in Active Crohn’s Disease
Paper